Why the study?
PMVR is effective for mitral regurgitation in high-risk patients who often have advanced age and comorbidities, but the prevalence and prognostic impact of frailty remained to be evaluated.
Does frailty impact clinical outcomes in patients undergoing percutaneous mitral valve repair?
Cohort
Does frailty impact clinical outcomes in patients undergoing percutaneous mitral valve repair?
Frailty screening may refine PMVR risk stratification; leaves open whether interventions improve outcomes.
Aim: Percutaneous mitral valve repair (PMVR) with MitraClip has proven to be an effective therapy to reduce mitral regurgitation in patients at high risk for conventional surgery. This population is currently characterized by advance age and high prevalence of comorbidities. Our aim was to evaluate the prevalence of frailty in a cohort of patients undergoing PMVR and its impact on clinical outcomes during follow-up.
No takes yet. Share an insight, caveat, or question.
Benito‐González et al. (2020) conducted a cohort in Mitral regurgitation. Frailty was evaluated on Clinical outcomes during follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: